Best Treatment for Childhood Epilepsy
- Publish Date: 2010/03/12
- Author: Oregon Health & Science University
Outline: Anti-seizure medications ethosuximide is the most effective treatment for childhood epilepsy.
Main DigestNew study identifies best treatment for childhood epilepsy - OHSU Doernbecher Children's Hospital is part of largest-ever NIH-funded pediatric epilepsy clinical trial to examine which of 3 standard treatments is most effective...
One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine .
OHSU Doernbecher Children's Hospital is one of 32 comprehensive pediatric epilepsy centers nationwide selected to participate in this landmark clinical trial as part of the NIH Childhood Absence Epilepsy Study Group.
The study group compared three medications typically used to treat the most common childhood epilepsy syndrome, childhood absence epilepsy, which is characterized by frequent non-convulsive seizures that cause the child to stop what he or she is doing and stare for up to 30 seconds at a time.
Prior to this study, there was no definitive evidence on which drug worked best.
"Much of our scientific understanding of childhood epilepsy care today comes from historical experience or studies involving adult patients with related, but not identical, conditions," explained Colin Roberts, M.D., OHSU Doernbecher's principal investigator for the study, assistant professor of pediatrics and neurology, and director of OHSU Doernbecher's Pediatric Epilepsy Program,
"This study is an important milestone in our understanding of childhood absence epilepsy. Never before have we been able to document in such a comprehensive, scientific fashion the best options to treat children with this condition."
The study group enrolled 453 children newly diagnosed with childhood absence epilepsy from July 2004 to October 2007. Study participants were randomly assigned to ethosuximide, valproic acid or lamotrigine. Drug doses were incrementally increased until the child was seizure-free. After 16 weeks of therapy, the researchers found ethosuximide and valproic acid were significantly more effective than lamotrigine in controlling seizures, with no intolerable side effects. They also determined ethosuximide was associated with significantly fewer negative effects on attention.
Nick and Michelle Skimas, of Vancouver, Wash., enrolled their daughter Julia in the study in April 2007. Julia stopped having seizures after starting medication.
Before diagnosis and treatment, Julia, now 8, would stop abruptly while reading aloud, pause for 10 to 15 seconds, then resume where she left off, not aware that anything had occurred. Michelle assumed Julia was just taking breaks to look at the pictures.
This went on for two to three weeks, and Michelle didn't think anything of it. Then, while on a family vacation, Julia suddenly stopped in the midst of pitching a baseball and began slowly turning in a circle. Julia was unaware of what was happening and had no recollection of what had occurred.
"That did it," said Michelle. "We took Julia to be evaluated as soon as we got back." After an EEG, and an MRI to rule out a brain tumor, Julia was diagnosed with childhood absence epilepsy. Her primary care physician recommended she enroll in a new drug trial at OHSU Doernbecher. Nick and Michelle were leery of giving their daughter medication, but Roberts and his team explained that without treatment Julia's seizures would have a serious impact on her learning and development.
"They said to think of Julia's brain as a classroom in which one child is continuously disruptive. The rest of the class can't function. It was a hard decision, but we are glad we participated. We feel blessed that she has been seizure-free for more than 2 1/2 years."
The national study group recommended long-term follow up for the study participants and recently received a five-year extension from the NIH.
Julia, who stopped taking the medication several months after she became seizure-free because it increased her BMI, or body mass index, continues to participate in the newly extended trial, representing one of three study groups: participants who took medication, became seizure-free and stopped taking the medication. The other groups comprise children who are taking the medication but still having seizures, and children taking the medication who are not experiencing seizures, respectively.
"We told Julia all along that what she was doing could very well help other kids in her position, and now she knows it did. That will make a big difference in her life," said Michelle.
"The initial outcomes from this study describe one of many aspects of childhood absence epilepsy evaluated by the study group. Collaborative studies like this lay the groundwork for many critically important studies to follow that will define the proper care of children with seizures," said Roberts.
The lead author for the study published in the New England Journal of Medicine is Tracy A. Glauser, M.D., of Cincinnati Children's Hospital and the University of Cincinnati College of Medicine. The study is supported by grants from the NIH.
About Childhood Absence Epilepsy
Childhood absence epilepsy is the most common form of pediatric epilepsy syndrome, accounting for up to 17 percent of all childhood epilepsy cases. It's characterized by frequent non-convulsive seizures that cause the child to stop what he or she is doing and stare. The sudden seizures can last five to 30 seconds. Following a seizure, the child resumes what he or she is doing without any awareness of what has happened. Left untreated, childhood absence epilepsy can interfere with a child's ability to learn and play. For more information about childhood absence epilepsy, visit www.epilepsyfoundation.org or www.epilepsy.com
OHSU Doernbecher Children's Hospital (www.ohsudoernbecher.com)
OHSU Doernbecher Children's Hospital is a world-class facility that each year cares for tens of thousands of children from Oregon, southwest Washington and around the nation, including national and international referrals for specialty care. Children have access to a full range of pediatric care, not just treatments for serious illness or injury, resulting in more than 120,000 outpatient visits, discharges, surgeries and pediatric transports annually.
Nationally recognized physicians at OHSU Doernbecher ensure children receive exceptional care, including outstanding cancer treatment, specialized neurology care and highly sophisticated heart surgery in the most patient- and family-centered environment. Pediatric experts from OHSU Doernbecher travel throughout Oregon and southwest Washington to provide specialty care to some 2,800 children at more than 154 outreach clinics in 13 locations.
- 1 - Osgood-Schlatters Disease: Causes, Diagnosis and Treatments | Disabled World | 2009/03/20
- 2 - Screening Lowers Severe Jaundice Risk in Babies | University of California San Francisco | 2009/09/28
- 3 - Jaundice in the Newborn Baby | Cecilia Koh | 2017/10/03
- 4 - Coaxing Kids Through Vaccinations - Pain Expectation is Pain Reality for Children | University of California - Riverside | 2018/06/04
- 5 - Fetal Alcohol Spectrum Disorder in Children | JoAnn Collins | 2009/03/23
- 6 - Types of Genetic Mutations Associated with Nephrotic Syndrome Identified | Fundação de Amparo à Pesquisa do Estado de São Paulo | 2018/03/24
- 7 - SIDS: Sudden Infant Death Syndrome Information | Disabled World | 2009/02/19
- 8 - Siblings of Cot Death Victims Have Four Times SIDS Risk | European Society of Cardiology | 2018/03/19
Help Spread Disability AwarenessConnect with Us on Social Media